Payment overview · 2025
General Payments
$226.48
9 reported records · 6 companies
Healthcare provider profile · identity verified
Anne Broad, MD
Allopathic & Osteopathic Physicians|Family Medicine · CADILLAC, MI · NPI 1225564248
Verified facts
What the public records show
CMS Open Payments records show Anne Broad, MD received $226.48 in general payments during 2025 across 9 reported records.
Inspire Medical Systems, Inc. accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $72.69 | 32.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.92 | 30.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.38 | 11.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.76 | 8.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.04 | 8.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.69 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $226.48 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $72.69 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.92 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.92 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 796 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 428 | 116 |
| Omeprazole | Omeprazole | 349 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 83 |
| Losartan Potassium | Losartan Potassium | 324 | 88 |
| Metformin Hcl | Metformin Hcl | 323 | 83 |
| Lisinopril | Lisinopril | 290 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 59 |
| Gabapentin | Gabapentin | 223 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 53 |
| Simvastatin | Simvastatin | 170 | 49 |
| Trulicity | Dulaglutide | 155 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 44 |
| Meloxicam | Meloxicam | 135 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 38 |
| Prednisone | Prednisone | 128 | 98 |
| Sertraline Hcl | Sertraline Hcl | 128 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 32 |
| Eliquis | Apixaban | 122 | 34 |
| Jardiance | Empagliflozin | 119 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 28 |
| Potassium Chloride | Potassium Chloride | 110 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 21 |
| Havrix | Hepatitis A Virus Vaccine/Pf | 100 | 98 |
| Metformin Hcl Er | Metformin Hcl | 84 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 29 |
| Donepezil Hcl | Donepezil Hcl | 76 | 25 |
| Buspirone Hcl | Buspirone Hcl | 75 | 24 |
| Montelukast Sodium | Montelukast Sodium | 73 | 20 |
| Ozempic | Semaglutide | 72 | 12 |
| Alprazolam | Alprazolam | 71 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 29 |
| Allopurinol | Allopurinol | 70 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 15 |
| Furosemide | Furosemide | 67 | 27 |
| Bupropion Xl | Bupropion Hcl | 64 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 20 |
| Tramadol Hcl | Tramadol Hcl | 62 | 13 |
| Ezetimibe | Ezetimibe | 60 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 58 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 57 | 15 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 55 | 55 |
| Mounjaro | Tirzepatide | 55 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 41 |
| Famotidine | Famotidine | 53 | 11 |
| Alendronate Sodium | Alendronate Sodium | 50 | 17 |
| Pregabalin | Pregabalin | 49 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Atenolol | Atenolol | 43 | 11 |
| Lorazepam | Lorazepam | 42 | 13 |
| Meclizine Hcl | Meclizine Hcl | 42 | 11 |
| Carvedilol | Carvedilol | 41 | 12 |
| Fenofibrate | Fenofibrate | 41 | 11 |
| Valacyclovir | Valacyclovir Hcl | 41 | 21 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 14 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 28 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $226.48 · 9 records | Inspire Medical Systems, Inc. | ABRYSVO, COMIRNATY, INSPIRE, Kerendia, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error